US3577491A - Tableting - Google Patents

Tableting Download PDF

Info

Publication number
US3577491A
US3577491A US1924*[A US3577491DA US3577491A US 3577491 A US3577491 A US 3577491A US 3577491D A US3577491D A US 3577491DA US 3577491 A US3577491 A US 3577491A
Authority
US
United States
Prior art keywords
fumaric acid
tablets
tableting
composition
tabletable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US1924*[A
Inventor
Peter Henry Cox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc
Application granted granted Critical
Publication of US3577491A publication Critical patent/US3577491A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent

Definitions

  • This invention relates to tableting and provides a new tableting lubricant which can be mixed with a powdered tabletable composition to aid during the compression thereof into tablets.
  • Tableting lubricants perform the general functions of providing (1) surface lubrication for the punch and die surfaces which come into contact with one another and with the compressed composition and (2) internal compression lubrication in order to lend pliability to the composition being compressed. Both of these lubrication functions must be satisfied if the powdered tabletable composition of interest is to be tableted at commercially acceptable rates in tableting machines operated at high speeds. Some prior lubricants have provided only one of these two necessary lubrication functions and hence have necessitated the use of a second lubricant. A general problem with these prior lubricants has been their insolubility which causes a tablet formed from an otherwise soluble composition to give a cloudy suspension rather than a clear solution when dissolved in water.
  • Talc and magnesium stearate are examples of such lubricants.
  • the use of other lubricants is restricted because of their toxicity. Examples are boric acid, benzoic acid and polyethylene glycol.
  • Some tableting lubricants such as sodium benzoate have therapeutic effects and therefore alter the pharmacological acceptability of tablets in which they are included.
  • fumaric acid provides the necessary tableting lubrication for powdered tabletable compositions and enables tablets to be compressed therefrom at high speeds. Fumaric acid does not impart addition toxicity of pharmaceutical activity to such compositions and has the advantage of being water soluble.
  • the fumaric acid tableting lubricant can be used with a 'wide range of powdered tabletable compositions to allow high speed testing theer of. While various amounts of fumaric acid can be mixed with such compositions depending upon the presence therein of ingredients which impart some lubrication and upon the tableting speed desired, it is usually sufiicient to use at least fumaric acid based on the total weight of the fumaric acid and the composition being tableted, when no other lubricants 3,577,491 Patented May 4, 1971 are used. If desired, fumaric acid may be used in large amounts, approaching the total tablet weight, since it is cohesive when compressed.
  • Fumaric acid is generally available as minute colorless monoclinic prisms which can be used in the present invention without further modification. If desired, these small prisms can be cornminuted to any desired fineness. Mesh sizes of 40 (United States Standard) and finer are particularly preferred for use with most powdered compositions. Fumaric acid has low toxicity and hence may be used for tablets which are intended to be taken internally. It appears to be unique in its tableting lubrication properties since its metal salts and homologous acids do not exhibit these properties. It has also been found that its stern-isomer, maleic acid, does not show the same lubrication properties.
  • the tabletable compositions which can be be lubricated for tableting with fumaric acid can be any compositions which are cohesive enough when compressed to form and retain a tablet shape.
  • Such compositions can be composed of powdered detergents, disinfectants, and/ or abrasives which disintegrate when placed in water to form cleaning solutions of various types.
  • the preferred compositions are effervescent mixtures, comprising an alkali metal carbonate or bicarbonate and an acid such as malic, citric or tartaric acids, which are capable of rapidly releasing carbon dioxide upon addition of water thereto. ⁇ Vhen the carbon dioxide has been released, the solution formed is useful for its al kalizing properties when taken orally.
  • compositions can also be composed of at least one therapeutic agent, a water-soluble excipient, and any necessary coloring or flavoring agents, diluents, binders, or disintegrators.
  • the therapeutic agent may be, e.g., acetylsalicylic acid, acetyl p-aminophenol or other analgesic.
  • binders may be added to the base composition to promote cohesion. All such compositions are tabletable in that they are cohesive when compressed, however, most of such compositions can be tableted only by hand since they cause binding and scoring of the punches and dies of power driven tableting machines. In order to attain commercial production speeds a tableting lubricant must be employed to reduce surface friction and internal compression friction.
  • the fumaric acid of the present invention may be used as the sole lubricant or may be employed in conjunction with another lubricant included in the tabletable composition. More particularly the fumaric acid lubricant can be substituted for various materials which function as tablet lubricants during compression.
  • fumaric acid provides the additional effect of taking part in the effervescent action.
  • the fumaric acid does form part of the effervescent couple it is neutralized to a metal salt, if a sufiicient amount of an alkaline material is employed, and in salt form is more highly soluble than is the free fumaric acid.
  • a source of alkali metal ions may be included in the pharmaceutical composition, so that upon dissolution of the composition in water the alkali metal salt of fumaric acid is formed and any solubility limitations of fumaric acid are eliminated.
  • this is not necessary because the fumaric acid is used in amounts low enough so that the volume of water normally used for dissolution of the tablets is suflicient to dissolve all the fumaric acid employed.
  • Amounts of at least 5% fumaric acid based on the total weight of the lubricated tabletable composition are generally sufficient to allow high-speed tableting when fumaric acid is used as the sole lubricant. When it is used as one of at least two tableting lubricants a proportionately smaller amount may be used. Amounts of from 5% to 14% fumaric acid allow tableting of efiervescent mixtures at rates up to about 5,000 tablets per minute on rotary tablet machines containing 47 punch and die sets. Each punch and die set produces approximately 106 tablets per minute in such machines. On a rotary machine containing 33 punch and die sets, tablets may be compressed at a rate of 76 tablets per minute per set for a total production of about 2,500 tablets per minute.
  • EXAMPLE 1 Component: Amount, gm. Sodium bicarbonate 500 Citric acid (anhydrous) 150 Fumaric acid 100 The above components in the amounts stated were dried and reduced to 30 mesh screen size and thoroughly mixed. The fumaric acid in the composition was present in an amount of 13.3 weight percent of the weight of the mixture. The citric acid was present in an amount of 20 weight percent and the sodium bicarbonate was present in an amount of 66.6 weight percent, both based on the total weight of the mixture.
  • the mixture was placed in a hopper of a hand-operated punch rotary tableting machine from which the mixture was fed to the dies of the punch and die sets of the machine.
  • the compression pressure was set at 8 tons/in
  • the tablets produced weighed approximately 3.6 gm. each.
  • the tablets Upon completion of the run the tablets were found to be smooth-surfaced and elegant in appearance. Upon dropping the same into about 100 ml. of room temperature water the tablets quickly eifervesced and dissolved to give a sparkling clear solution with no sediment. Such a solution can be taken orally to provide an alkalizing effect in the users stomach.
  • EXAMPLE 2 Component: Amount, gm. Sodium bicarbonate 500 Malic acid 150 Fumaric acid 100 The above components were dried, reduced to 30 mesh screen size and mixed. The mixed composition was then added to the hopper of a hand-operated punch rotary tableting machine and tablets were made. Each tablet weighed approximately 3.6 gm.
  • the tablet had the same dissolving and effervescent characteristics as the tablets of Example 1.
  • EXAMPLE 3 Component: Amount, gm. Sodium bicarbonate 4000 Citric acid (anhydrous) 1200 Fumaric acid 800 The sodium bicarbonate was dried and then mixed with both the citric acid and the fumaric acid and the resulting mixture then passed through a mill operating at 4500 rpm. containing an 8 mesh screen and compressed into three gram tablets on a single punch, one station machine set for 8 to 10 tons per square inch pressure. The tablets produced were uniform and smooth-surfaced, and were one inch in diameter and 0.2 inch thick. A first portion of these tablets was stacked in capped bottles and stored at 40 C. for one month and a second portion was similarly stored at 50 C. for the same period of time. The tablets from both portions appeared to be unchanged upon testing after these stability studies. Both before and after storage under the accelerated storage conditions the tablets dissolved in about 100 ml. of 43 C. water in about 25 seconds to produce a completely clear solution.
  • EXAMPLE 4 Component: Amount, gm. Sodium bicarbonate 4380 Citric acid (anhydrous)) 1320 Fumaric acid 300 The sodium bicarbonate was dried and then blended with a mixture of the citric acid and the fumaric acid. Three (3) gram tablets of 1.0 inch diameter and 0.14 inch thickness were run on a single punch, one station tableting machine. These tablets showed slight scoring but were otherwise of good quality, indicating that 5% fumaric acid based on the total tablet weight provides sufiicient tableting lubrication. The tablets showed a one minute dissolution time in 180 ml. of water at 16 C.
  • EXAMPLE 5 Component: Amount, gm. Sodium bicarbonate 2100 Citric acid (anhydrous) 660' Fumaric acid 100 Acetylsalicylic acid 81 The sodium bicarbonate was dried and the materials were then mixed in order of increasing amounts. Tablets of 1.0 inch diameter and 0.20 inch thickness weighing 3.03 gm. each were run on a single punch, one station tableting machine. These tablets were of elegant appearance and exhibited an seconds dissolution time when placed in 180 ml. of water at 16 C. Upon dissolution of one tablet 1.25 grains of aspirin (acetylsalicylic acid) were released into the water, which amount is that recommended for children.
  • EXAMPLE 6 Component: Amount, gm. Dicalcium phosphate dihydrate 340 Confectionery cane sugar 56.7 Gelatin, U.S.P. 3.3 Fumaric acid The first three above components were mixed with the fumaric acid to make an initial mixture containing 20% fumaric acid. Two hundred (200) gm. of this composition were formed into placebo tablets on a single punch tableting machine at a rate of about tablets per minute. The tablets had diameters of about 0.375 inch and thicknesses of about 0.22 inch and disintegrated slowly in room temperature water.
  • fumaric acid can be used as a tableting lubricant for powdered tabletable compositions. Generally at least 5% fumaric acid on the basis of the total tablet weight is used, although lesser amounts are usable.
  • the improvement comprising homogeneously intermixing with said composition prior to compression thereof, as the essential lubricant, a dry-mixable free flowing lubricant powder comprising fumaric acid,
  • said powdered tabletable composition is a fumaric acid-free efiervescent mixture of a base and an acid.
  • said powdered tabletable composition includes acetylsalicylic acid and 6 wherein the amount of said fumaric acid is sufiicient to allow high speed tableting of said composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

AN IMPROVEMENT IN THE PROCESS OF COMPRESSING POWDERED TABLETABLE COMPOSITIONS IS GAINED BY MIXING FUMARIC ACID WITH SAID COMPOSITION PRIOR TO COMPRESSION. THE FUMARIC ACID ACTS AS A SURFACE LUBRICANT AND AS AN INTERNAL COMPRESSION LUBRICANT FOR SAID TABLETABLE COMPOSITIONS. THE POWDERED TABLETABLE COMPOSITIONS LUBRICATED WITH FUMARIC ACID CAN BE THOSE INTENDED FOR INTERNAL EMPLOYMENT SUCH AS FOR ALKALIZING OF THE STOMACH OR INTENDED FOR EXTERNAL USE SUCH AS FOR GENERAL CLEANING OF SOLID SURFACES.

Description

United States Patent 3,577,491 TABLETING Peter Henry Cox, Oss, Netherlands, assignor to Miles Laboratories Incorporated, Elkhart, Ind.
No Drawing. Original application Jan. 2, 1968, Ser. No. 694,890, now Patent No. 3,518,346, dated June 30, 1970. Divided and this application Dec. 29, 1969, Ser. No. 1,924
Int. Cl. A615 3/10; Afilk 7/16 US. Cl. 264120 7 Claims ABSTRACT OF THE DESCLOSURE This is a division of application Ser. No. 694,890, filed Jan. 2, 1968, now U.S. Pat. No. 3,518,346.
This invention relates to tableting and provides a new tableting lubricant which can be mixed with a powdered tabletable composition to aid during the compression thereof into tablets.
Tableting lubricants perform the general functions of providing (1) surface lubrication for the punch and die surfaces which come into contact with one another and with the compressed composition and (2) internal compression lubrication in order to lend pliability to the composition being compressed. Both of these lubrication functions must be satisfied if the powdered tabletable composition of interest is to be tableted at commercially acceptable rates in tableting machines operated at high speeds. Some prior lubricants have provided only one of these two necessary lubrication functions and hence have necessitated the use of a second lubricant. A general problem with these prior lubricants has been their insolubility which causes a tablet formed from an otherwise soluble composition to give a cloudy suspension rather than a clear solution when dissolved in water. Talc and magnesium stearate are examples of such lubricants. The use of other lubricants is restricted because of their toxicity. Examples are boric acid, benzoic acid and polyethylene glycol. Some tableting lubricants such as sodium benzoate have therapeutic effects and therefore alter the pharmacological acceptability of tablets in which they are included.
It has not been found that fumaric acid provides the necessary tableting lubrication for powdered tabletable compositions and enables tablets to be compressed therefrom at high speeds. Fumaric acid does not impart addition toxicity of pharmaceutical activity to such compositions and has the advantage of being water soluble.
Accordingly, it is an object of this invention to provide a process for making a tablet which comprises compressing a mixture of fumaric acid and a powdered tabletable composition.
The fumaric acid tableting lubricant can be used with a 'wide range of powdered tabletable compositions to allow high speed testing theer of. While various amounts of fumaric acid can be mixed with such compositions depending upon the presence therein of ingredients which impart some lubrication and upon the tableting speed desired, it is usually sufiicient to use at least fumaric acid based on the total weight of the fumaric acid and the composition being tableted, when no other lubricants 3,577,491 Patented May 4, 1971 are used. If desired, fumaric acid may be used in large amounts, approaching the total tablet weight, since it is cohesive when compressed.
Fumaric acid is generally available as minute colorless monoclinic prisms which can be used in the present invention without further modification. If desired, these small prisms can be cornminuted to any desired fineness. Mesh sizes of 40 (United States Standard) and finer are particularly preferred for use with most powdered compositions. Fumaric acid has low toxicity and hence may be used for tablets which are intended to be taken internally. It appears to be unique in its tableting lubrication properties since its metal salts and homologous acids do not exhibit these properties. It has also been found that its stern-isomer, maleic acid, does not show the same lubrication properties.
The tabletable compositions which can be be lubricated for tableting with fumaric acid can be any compositions which are cohesive enough when compressed to form and retain a tablet shape. Such compositions can be composed of powdered detergents, disinfectants, and/ or abrasives which disintegrate when placed in water to form cleaning solutions of various types. The preferred compositions are effervescent mixtures, comprising an alkali metal carbonate or bicarbonate and an acid such as malic, citric or tartaric acids, which are capable of rapidly releasing carbon dioxide upon addition of water thereto. \Vhen the carbon dioxide has been released, the solution formed is useful for its al kalizing properties when taken orally. The compositions can also be composed of at least one therapeutic agent, a water-soluble excipient, and any necessary coloring or flavoring agents, diluents, binders, or disintegrators. In such compositions the therapeutic agent may be, e.g., acetylsalicylic acid, acetyl p-aminophenol or other analgesic. If necessary, binders may be added to the base composition to promote cohesion. All such compositions are tabletable in that they are cohesive when compressed, however, most of such compositions can be tableted only by hand since they cause binding and scoring of the punches and dies of power driven tableting machines. In order to attain commercial production speeds a tableting lubricant must be employed to reduce surface friction and internal compression friction.
The fumaric acid of the present invention may be used as the sole lubricant or may be employed in conjunction with another lubricant included in the tabletable composition. More particularly the fumaric acid lubricant can be substituted for various materials which function as tablet lubricants during compression.
In effervescent tablets, fumaric acid provides the additional effect of taking part in the effervescent action. When the fumaric acid does form part of the effervescent couple it is neutralized to a metal salt, if a sufiicient amount of an alkaline material is employed, and in salt form is more highly soluble than is the free fumaric acid. Hence, when greater solubility than that for free fumaric acid is desired, a source of alkali metal ions may be included in the pharmaceutical composition, so that upon dissolution of the composition in water the alkali metal salt of fumaric acid is formed and any solubility limitations of fumaric acid are eliminated. Generally, however, this is not necessary because the fumaric acid is used in amounts low enough so that the volume of water normally used for dissolution of the tablets is suflicient to dissolve all the fumaric acid employed.
Amounts of at least 5% fumaric acid based on the total weight of the lubricated tabletable composition are generally sufficient to allow high-speed tableting when fumaric acid is used as the sole lubricant. When it is used as one of at least two tableting lubricants a proportionately smaller amount may be used. Amounts of from 5% to 14% fumaric acid allow tableting of efiervescent mixtures at rates up to about 5,000 tablets per minute on rotary tablet machines containing 47 punch and die sets. Each punch and die set produces approximately 106 tablets per minute in such machines. On a rotary machine containing 33 punch and die sets, tablets may be compressed at a rate of 76 tablets per minute per set for a total production of about 2,500 tablets per minute.
The following examples illustrate the invention. The concentrations of components are stated as weight percent of the weight of the lubricated composition as tableted.
EXAMPLE 1 Component: Amount, gm. Sodium bicarbonate 500 Citric acid (anhydrous) 150 Fumaric acid 100 The above components in the amounts stated were dried and reduced to 30 mesh screen size and thoroughly mixed. The fumaric acid in the composition was present in an amount of 13.3 weight percent of the weight of the mixture. The citric acid was present in an amount of 20 weight percent and the sodium bicarbonate was present in an amount of 66.6 weight percent, both based on the total weight of the mixture.
The mixture was placed in a hopper of a hand-operated punch rotary tableting machine from which the mixture was fed to the dies of the punch and die sets of the machine. The compression pressure was set at 8 tons/in The tablets produced weighed approximately 3.6 gm. each.
Upon completion of the run the tablets were found to be smooth-surfaced and elegant in appearance. Upon dropping the same into about 100 ml. of room temperature water the tablets quickly eifervesced and dissolved to give a sparkling clear solution with no sediment. Such a solution can be taken orally to provide an alkalizing effect in the users stomach.
EXAMPLE 2 Component: Amount, gm. Sodium bicarbonate 500 Malic acid 150 Fumaric acid 100 The above components were dried, reduced to 30 mesh screen size and mixed. The mixed composition was then added to the hopper of a hand-operated punch rotary tableting machine and tablets were made. Each tablet weighed approximately 3.6 gm.
The tablet had the same dissolving and effervescent characteristics as the tablets of Example 1.
EXAMPLE 3 Component: Amount, gm. Sodium bicarbonate 4000 Citric acid (anhydrous) 1200 Fumaric acid 800 The sodium bicarbonate was dried and then mixed with both the citric acid and the fumaric acid and the resulting mixture then passed through a mill operating at 4500 rpm. containing an 8 mesh screen and compressed into three gram tablets on a single punch, one station machine set for 8 to 10 tons per square inch pressure. The tablets produced were uniform and smooth-surfaced, and were one inch in diameter and 0.2 inch thick. A first portion of these tablets was stacked in capped bottles and stored at 40 C. for one month and a second portion was similarly stored at 50 C. for the same period of time. The tablets from both portions appeared to be unchanged upon testing after these stability studies. Both before and after storage under the accelerated storage conditions the tablets dissolved in about 100 ml. of 43 C. water in about 25 seconds to produce a completely clear solution.
4 EXAMPLE 4 Component: Amount, gm. Sodium bicarbonate 4380 Citric acid (anhydrous)) 1320 Fumaric acid 300 The sodium bicarbonate was dried and then blended with a mixture of the citric acid and the fumaric acid. Three (3) gram tablets of 1.0 inch diameter and 0.14 inch thickness were run on a single punch, one station tableting machine. These tablets showed slight scoring but were otherwise of good quality, indicating that 5% fumaric acid based on the total tablet weight provides sufiicient tableting lubrication. The tablets showed a one minute dissolution time in 180 ml. of water at 16 C.
EXAMPLE 5 Component: Amount, gm. Sodium bicarbonate 2100 Citric acid (anhydrous) 660' Fumaric acid 100 Acetylsalicylic acid 81 The sodium bicarbonate was dried and the materials were then mixed in order of increasing amounts. Tablets of 1.0 inch diameter and 0.20 inch thickness weighing 3.03 gm. each were run on a single punch, one station tableting machine. These tablets were of elegant appearance and exhibited an seconds dissolution time when placed in 180 ml. of water at 16 C. Upon dissolution of one tablet 1.25 grains of aspirin (acetylsalicylic acid) were released into the water, which amount is that recommended for children.
EXAMPLE 6 Component: Amount, gm. Dicalcium phosphate dihydrate 340 Confectionery cane sugar 56.7 Gelatin, U.S.P. 3.3 Fumaric acid The first three above components were mixed with the fumaric acid to make an initial mixture containing 20% fumaric acid. Two hundred (200) gm. of this composition were formed into placebo tablets on a single punch tableting machine at a rate of about tablets per minute. The tablets had diameters of about 0.375 inch and thicknesses of about 0.22 inch and disintegrated slowly in room temperature water.
An additional three hundred (300) gm. of the first three components in the same proportions as given above were then mixed with an equal amount of the initial mixture and 400 gm. of the resulting mixture tableted as above. These tablets contained 10% fumaric acid based on the total tablet weight and showed the same slow disintegration rate as the above tablets. The remaining 200 gm. of the composition used for these tablets was then mixed with an additional 200 gm. of the first three components in the same proportions as given above. The resulting mixture containing 5% fumaric acid was tableted as above and the tablets exhibited similar properties.
All of the tablets produced were hard surfaced and elegant in appearance.
In summary, fumaric acid can be used as a tableting lubricant for powdered tabletable compositions. Generally at least 5% fumaric acid on the basis of the total tablet weight is used, although lesser amounts are usable.
What is claimed is:
1. In the process of imparting free-flowing dry, powdery lubrication for the surfaces of the punch and die walls of high-speed power-driven machines producing tablets by compressing a dry, free-flowing powdered tabletable composition otherwise causing binding and scoring of the punches and dies of power-driven tableting machines, aiding the flow of such composition into the dies of tableting machines and, upon compression and subsequent ejection of the tabletable composition, aiding in maintaining the punch and die surfaces free from any retained composition which would otherwise, if allowed to build up, cause poor tableting characteristics,
the improvement comprising homogeneously intermixing with said composition prior to compression thereof, as the essential lubricant, a dry-mixable free flowing lubricant powder comprising fumaric acid,
compressing the free-flowing, dry, powdery, homogeneous intermixture into cohesive tablets in the punch and dies of a high-speed power-driven tablet machine,
ejecting the tablets from the dies,
repeating said compressing and ejecting steps at optimum high-speed tableting rates permitted for each punch and die set in such machine,
with the result that the punch faces and die wall surfaces of high-speed power-driven tablet machines are free from any visible retained composition which would otherwise, if allowed to build up, cause poor tableting characteristics.
2. The process of claim 1 wherein said powdered tabletable composition is a fumaric acid-free efiervescent mixture of a base and an acid.
3. The process of claim 1 wherein said mixing step is conducted with at least about 5% fumaric acid based on the total weight of said fumaric and said powdered tabletable composition.
4. The process of claim 1 wherein said tablet is compressed in a high-speed cycle and said powdered tabletable composition is a fumaric acid-free efiervescent mixture of a base and an acid.
5. The process of claim 1 wherein said powdered tabletable composition includes a therapeutic agent.
6. The process of claim 1 wherein said powdered tabletable composition includes acetylsalicylic acid and 6 wherein the amount of said fumaric acid is sufiicient to allow high speed tableting of said composition.
7. The process of claim 1 wherein said fumaric acid is present in an amount of about from 5% to 14% based on the total weight of said fumaric acid and said powdered tabletable composition and wherein said composition is a fumaric acid-free efiervescent mixture of a base and an acid.
References Cited UNITED STATES PATENTS 2,035,267 3/1936 Fleischman 42453 2,913,373 11/1959 Weisz et al. 42452 3,082,091 3/1963 Smith et al. 42444 3,105,792 10/1963 White 424--44 3,136,692 6/1964 Bandelin 424-44 3,282,792 11/1966 Fiscella 424-52 3,355,392 511/1967 Cantor et a1 424329X 3,382,150 5/1968 Grass et al. 424-32 3,245,798 4/1966 Van Ness 99-78 3.330,665 7/1967 Van Ness et a1 9978 3,330,775 7/ 1967 Marquis 252-363.5 3,370,956 2/1968 Reitman et al. 9978 FOREIGN PATENTS 6,503,367 9/ 1965 Netherlands.
6,509,856 1/ 1966 Netherlands.
6,516,003 6/1966 Netherlands.
1,243,597 6/1967 Germany.
SHEP K. ROSE, Pirmary Examiner US. Cl. X.R.
US1924*[A 1968-01-02 1969-12-29 Tableting Expired - Lifetime US3577491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69489068A 1968-01-02 1968-01-02
US192469A 1969-12-29 1969-12-29

Publications (1)

Publication Number Publication Date
US3577491A true US3577491A (en) 1971-05-04

Family

ID=26669679

Family Applications (1)

Application Number Title Priority Date Filing Date
US1924*[A Expired - Lifetime US3577491A (en) 1968-01-02 1969-12-29 Tableting

Country Status (1)

Country Link
US (1) US3577491A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4153678A (en) * 1978-07-17 1979-05-08 American Cyanamid Company Levamisole effervescent tablets
EP0185347A2 (en) * 1984-12-17 1986-06-25 Chugai Seiyaku Kabushiki Kaisha Method for production of stable nicorandil preparation
EP0218148A1 (en) * 1985-09-26 1987-04-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical composition
JPH0899906A (en) * 1995-01-17 1996-04-16 Chugai Pharmaceut Co Ltd Sustained release pharmaceutical preparation containing fumaric acid
US5922351A (en) * 1991-03-27 1999-07-13 Bayer Corporation Lubricants for use in tabletting

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4153678A (en) * 1978-07-17 1979-05-08 American Cyanamid Company Levamisole effervescent tablets
US4803213A (en) * 1984-12-17 1989-02-07 Chugai Seiyaku Kabushiki Kaisha Method for production of stable nicorandil preparation
EP0185347A2 (en) * 1984-12-17 1986-06-25 Chugai Seiyaku Kabushiki Kaisha Method for production of stable nicorandil preparation
EP0185347A3 (en) * 1984-12-17 1987-04-22 Chugai Seiyaku Kabushiki Kaisha Method for production of stable nicorandil preparation
AU579431B2 (en) * 1984-12-17 1988-11-24 Chugai Seiyaku Kabushiki Kaisha Method for production of stable nicorandil preparation
EP0218148A1 (en) * 1985-09-26 1987-04-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical composition
EP0386801A2 (en) * 1985-09-26 1990-09-12 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical composition
EP0386801A3 (en) * 1985-09-26 1990-11-07 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical composition
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US5922351A (en) * 1991-03-27 1999-07-13 Bayer Corporation Lubricants for use in tabletting
JPH0899906A (en) * 1995-01-17 1996-04-16 Chugai Pharmaceut Co Ltd Sustained release pharmaceutical preparation containing fumaric acid
JP2535141B2 (en) * 1995-01-17 1996-09-18 中外製薬株式会社 Fumaric acid-containing sustained-release preparation

Similar Documents

Publication Publication Date Title
US3136692A (en) Effervescent composition containing polyvinylpyrrolidone
US4832956A (en) Disintegrating tablet and process for its preparation
US3293132A (en) Spray dried vitamin compositions and method of preparation
US2540253A (en) Granulation process
US2985562A (en) Effervescent compositions
US3341415A (en) Pharmaceutical tablet excipients of solid particles of a binary solid solution of mannitol with a sugar
US5609883A (en) Compressed tablet transitory lubricant system
JPH05501260A (en) Direct compression carrier composition
US3590117A (en) Long-lasting troche containing guar gum
KR920005979A (en) Pharmaceutical composition with excellent taste containing porous particles and method for preparing the pharmaceutical composition
US3453368A (en) Smaller high potency compressed tablets of ascorbic acid
US3632778A (en) Tablets containing l-dopa
US3976601A (en) Water soluble lubricant for tabletting compositions
KR940000007B1 (en) Process for preparing effervescent acetylsalicylic acid tablets
US3518344A (en) Tableting lubricant
US3577491A (en) Tableting
US2980589A (en) Process for producing anhydrous granulation of a medicinally active waterlabile powder
US3506756A (en) Use of adipic acid as a tableting lubricant
US4536389A (en) Bactericidal tabletting composition and tablets formed therefrom
US3584099A (en) Adipic acid as a tableting lubricant
US3577492A (en) Tableting lubricant
US3518346A (en) Tableting
GB1274797A (en) Effervescent tablets and powders
US3493659A (en) Compositions and process for the production thereof
NO128051B (en)